Nicorandil as Anti-inflammatory in Rheumatoid Arthritis
Recruiting · NCT07516769 · Interventional (participants receive a specific treatment) · Lead sponsor: Tanta University
View the official record on ClinicalTrials.gov →Interventions studied
Nicorandil 5 MG Oral Tablet
What this trial is about
This study aims to evaluate the possible efficacy and safety of nicorandil as anti-inflammatory in managing patients with active rheumatoid arthritis.
Who can take part
Age range
18 Years to 70 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 3
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients with active rheumatoid arthritis (not in remission) according to American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) i.e., 28 joints disease activity score (DAS-28) \>2.6.
- Patients receiving the conventional DMARDs
Exclusion criteria
- Patients with heart disease (congestive heart failure, arrhythmia and ischemic heart disease), diabetes, active infection, and other illness except rheumatoid arthritis.
- Patients with severe renal and hepatic dysfunction. - Patients receiving biological DMARDs.
- Patients receiving oral prednisolone greater than 15mg/day.
- Patients with hypersensitivity to study medications.
- Patients using antioxidants.
- Pregnant and lactating females.
Where it is running
1 location listed.
- Tanta university - Tanta, Gharbia Governorate, Egypt